Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (2623)	11/9/2010 4:42:44 PM
From: DewDiligence_on_SI	Read Replies (1) \| Respond to of 3027

>Anybody else think that teva's raising questions about the approval process with the fda in October doesn't reconcile well with expecting approval by year end?< “Doesn’t reconcile well” is quite an understatement on your part :-) If Teva thought it had any chance whatsoever of getting FDA approval for Lovenox, the last thing they would want to do is publicly criticize the FDA’s handling of their Lovenox ANDA. The object of Teva’s bitching, moaning, and dissembling is not Lovenox, but rather Copaxone. I commented on this in siliconinvestor.com . Regards, Dew